Last reviewed · How we verify
NCT06880055: SOLAR
Shield Post-Approval Study Protocol
trial testing Shield Blood Test for colo-rectal cancer Screening in Colo-rectal Cancer in 3,375 participants. Currently enrolling.
1 September 2030
Quick facts
| Lead sponsor | Guardant Health, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,375 |
| Start date | 14 July 2025 |
| Primary completion | 1 September 2030 |
| Estimated completion | 1 December 2030 |
| Sites | 56 locations across United States |
Drugs / interventions tested
- Shield Blood Test for colo-rectal cancer Screening
Conditions studied
- Colo-rectal Cancer — all drugs for Colo-rectal Cancer →
Sponsor
Guardant Health, Inc.
Who can join
Adults 45 to 81, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.
Anees M, Sherry C, Park HY, Grayhack EE, et al · · 2026 · PMID 41866828 · DOI 10.1002/ctm2.70594
Verify or expand the search:
- PubMed search for NCT06880055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colo-rectal Cancer
Currently open trials in the same condition.
- NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
- NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
- NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting
- NCT07003022 — Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC · Phase 2 · recruiting
Other Guardant Health, Inc. trials
Trials by the same sponsor.
- NCT05935384 — SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation · recruiting
- NCT05117840 — Screening for High Frequency Malignant Disease · active not recruiting
- NCT04436393 — Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer · completed
- NCT04136002 — Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode · completed
- NCT03625557 — Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06880055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guardant Health, Inc.
- Last refreshed: 19 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06880055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing